Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H48O3 |
Molecular Weight | 456.7003 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@]3(C)[C@]([H])(CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@]5(C)CC[C@@]34C)[C@@]1(C)CC[C@@H](O)[C@]2(C)C(O)=O
InChI
InChIKey=NBGQZFQREPIKMG-PONOSELZSA-N
InChI=1S/C30H48O3/c1-18-10-13-26(3)16-17-28(5)20(24(26)19(18)2)8-9-21-27(4)14-12-23(31)30(7,25(32)33)22(27)11-15-29(21,28)6/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21-,22-,23-,24+,26-,27-,28-,29-,30-/m1/s1
Molecular Formula | C30H48O3 |
Molecular Weight | 456.7003 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 11 / 11 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Β-boswellic acid (β-BA) is one of the active triterpenoid compounds from the extract of boswellia serrate, known in Indian Ayurvedic system of medicine as Salai guggal. Beta-boswellic acid has been indicated in apoptosis of cancer cells. β-boswellic acid belonds to class of boswellic acids exhibiting anti-inflammatory activities, which are in the phase II clinical trial for study of safety and tolerability in subjects with Relapsing Remitting Multiple Sclerosis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL215 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19374837 |
23.9 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Mechanism of antiinflammatory actions of curcumine and boswellic acids. | 1993 Mar |
|
Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. | 1998 Nov 17 |
|
Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. | 2002 Dec |
|
Effects of Boswellia serrata in mouse models of chemically induced colitis. | 2005 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01450124
8 months of treatment at three times a day dose of between 400-1600 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26482008
β-boswellic acid (β-BA) significantly increases nitric oxide (NO) production in human umbilical vein endothelial cells (HUVECs). HEUVCs were pretreated with β-BA (25 and 50 uM) for 24 h before being subjected to 6 h OGD then incubated with β-BA for an additional 24 h. NO production was measured by DAF-FM DA. The amount of NO was evaluated by measuring the fluorescence intensity excited at 495 nm and emitted at 515 nm.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:07:44 GMT 2023
by
admin
on
Sat Dec 16 05:07:44 GMT 2023
|
Record UNII |
B252M1YO2V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID2057578
Created by
admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
|
PRIMARY | |||
|
m2628
Created by
admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
168928
Created by
admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
|
PRIMARY | |||
|
631-69-6
Created by
admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
|
PRIMARY | |||
|
B252M1YO2V
Created by
admin on Sat Dec 16 05:07:44 GMT 2023 , Edited by admin on Sat Dec 16 05:07:44 GMT 2023
|
PRIMARY |